Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canfosfamide + liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Telik
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
**Canfosfamide + liposomal doxorubicin** is a combination of two distinct anticancer agents. **Canfosfamide** is a glutathione analog prodrug activated by the enzyme glutathione S-transferase P1-1, leading to induction of apoptosis primarily in tumor cells with elevated GST P1-1 levels. **Liposomal doxorubicin** (specifically pegylated, branded as Doxil) is an anthracycline antibiotic encapsulated in liposomes with a polyethylene glycol (PEG) coating, which prolongs circulation and selectively enhances delivery to tumors. This combination has been extensively studied in platinum-refractory or -resistant ovarian cancer, leveraging the potential synergy between GST-activated cytotoxicity and improved drug delivery to tumor tissue. The regimen has demonstrated manageable toxicity profiles, with some studies showing improved disease stabilization and response rates in specific subgroups, but failed to achieve statistically significant superiority over standard single-agent regimens in large Phase III trials.
- Brand names
- TelcytaDoxilCAELYX
- Other names
- pegylated liposomal doxorubicinPLDcanfosfamide HCl
02
Targets
GSTP1 (Glutathione S-transferase P)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on canfosfamide + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canfosfamide + liposomal doxorubicin.